Streptomycin adverse reactions: Difference between revisions
Gerald Chi (talk | contribs) Created page with "__NOTOC__ {{Streptomycin}} {{CMG}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = STREPTOMYCIN INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION ..." |
Gerald Chi (talk | contribs) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Adverse Reactions== | |||
The following reactions are common: vestibular [[ototoxicity]] ([[nausea]], [[vomiting]], and [[vertigo]]); [[paresthesia]] of face; [[rash]]; [[fever]]; [[urticaria]]; angioneurotic edema; and [[eosinophilia]]. | |||
The following reactions are less frequent: cochlear ototoxicity ([[deafness]]); [[exfoliative dermatitis]]; [[anaphylaxis]]; [[azotemia]]; [[leucopenia]]; [[thrombocytopenia]]; [[pancytopenia]]; [[hemolytic anemia]]; [[muscular weakness]]; and [[amblyopia]]. | |||
Vestibular dysfunction resulting from the parenteral administration of streptomycin is cumulatively related to the total daily dose. When 1.8 to 2 g/day are given, symptoms are likely to develop in the large percentage of patients - especially in the elderly or patients with impaired renal function - within four weeks. Therefore, it is recommended that caloric and audiometric tests be done prior to, during, and following intensive therapy with streptomycin in order to facilitate detection of any vestibular dysfunction and/or impairment of hearing which may occur. | |||
Vestibular symptoms generally appear early and usually are reversible with early detection and cessation of streptomycin administration. Two to three months after stopping the drug, gross vestibular symptoms usually disappear, except from the relative inability to walk in total darkness or on very rough terrain. | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = STREPTOMYCIN INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [X-GEN PHARMACEUTICALS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=abd1f64e-4283-4370-aae8-3666316aa36e | publisher = | date = | accessdate = }}</ref> | Although streptomycin is the least nephrotoxic of the [[aminoglycosides]], [[nephrotoxicity]] does occur rarely. | ||
Clinical judgment as to termination of therapy must be exercised when side effects occur.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = STREPTOMYCIN INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [X-GEN PHARMACEUTICALS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=abd1f64e-4283-4370-aae8-3666316aa36e | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 18:44, 7 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Adverse Reactions
The following reactions are common: vestibular ototoxicity (nausea, vomiting, and vertigo); paresthesia of face; rash; fever; urticaria; angioneurotic edema; and eosinophilia.
The following reactions are less frequent: cochlear ototoxicity (deafness); exfoliative dermatitis; anaphylaxis; azotemia; leucopenia; thrombocytopenia; pancytopenia; hemolytic anemia; muscular weakness; and amblyopia.
Vestibular dysfunction resulting from the parenteral administration of streptomycin is cumulatively related to the total daily dose. When 1.8 to 2 g/day are given, symptoms are likely to develop in the large percentage of patients - especially in the elderly or patients with impaired renal function - within four weeks. Therefore, it is recommended that caloric and audiometric tests be done prior to, during, and following intensive therapy with streptomycin in order to facilitate detection of any vestibular dysfunction and/or impairment of hearing which may occur.
Vestibular symptoms generally appear early and usually are reversible with early detection and cessation of streptomycin administration. Two to three months after stopping the drug, gross vestibular symptoms usually disappear, except from the relative inability to walk in total darkness or on very rough terrain.
Although streptomycin is the least nephrotoxic of the aminoglycosides, nephrotoxicity does occur rarely.
Clinical judgment as to termination of therapy must be exercised when side effects occur.[1]
References
Adapted from the FDA Package Insert.